Crossmark

Assessing the sustainability of compliance with surgical site infection prophylaxis after discontinuation of mandatory active reporting: study protocol

Crossref DOI link: https://doi.org/10.1186/s43058-022-00288-0

Published Online: 2022-04-25

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Branch-Elliman, Westyn https://orcid.org/0000-0002-9658-5124
Elwy, A. Rani

Lamkin, Rebecca L.

Shin, Marlena

Engle, Ryann L.

Colborn, Kathryn

Rove, Jessica

Pendergast, Jacquelyn

Hederstedt, Kierstin

Hawn, Mary

Mull, Hillary J.
Funding

Funding for this research was provided by:

Health Services Research and Development (IIR 20-101)
License Information

Text and Data Mining valid from 2022-04-25

Version of Record valid from 2022-04-25
More Information

Article History

Received: 2 March 2022

Accepted: 22 March 2022

First Online: 25 April 2022

Declarations

:

: Not applicable.

: Not applicable.

: WBE was the site PI of a COVID-19 therapeutics trial funded by Gilead Sciences (funds to institution). WBE is a paid expert witness for DLA Piper, LLC, Medtronic, and CRICO. All other authors report no conflicts of interest.The views expressed are those of the authors and do not necessarily represent those of the US Federal Government or the Department of Veterans Affairs.

Document is current

Any future updates will be listed below